Excelra and AsedaSciences® announce a strategic Co-Marketing Agreement
Schindellegi, Switzerland, June 2024 – Small molecule toxicity assessment remains a hurdle in drug development, and it requires the accurate assessment of the potential toxicity of the small molecule candidates early in development. To address this, AsedaSciences and Excelra are joining hands. Aseda Sciences is a leading global innovator in generating, analyzing, and visualizing high-quality predictive small molecule data and Excelra is a leading global data and digital insights organization.
This strategic agreement with Excelra, aims to co-market and expand the reach of AsedaSciences’ groundbreaking 3RnD® platform which will be strengthened with Excelra’s 10M+ chemical structure and growing GOSTAR® database. This sets a new benchmark for information consolidation and providing content accessibility through a single, easy-to-use interface for the scientific community.
The 3RnD platform, developed by AsedaSciences, represents a new standard in the integration and visualization of high-quality data from validated New Approach Methods (NAMs), to support the selection, prioritization and progression of safer compounds. This cloud-based, AI-driven risk assessment tool empowers scientists to rapidly visualize and understand the relationship between chemical structures and their biological effects. By incorporating GOSTAR data, an extensive small molecule database that provides invaluable structure-activity relationship (SAR) information, AsedaSciences reinforces its commitment to drug discovery and development.
This collaboration reflects both companies’ shared dedication to enhancing drug discovery and development while prioritizing patient and environmental safety and sustainability. The collaboration will provide scientists worldwide access to advanced tools, data, and curated information on millions of compound structures within an easy-to-use platform. This will save time and enhance decision-making efficiency and productivity in drug discovery and development.
“Partnering with Excelra is a strategic step towards amplifying AsedaSciences’s commitment to supporting global drug discovery efforts through data integration and visual transformation to support the design of safer compounds and improve productivity,” said Brad Calvin, CEO of AsedaSciences. He continued:
The integration of GOSTAR into our 3RnD platform enables us to offer unparalleled insights and analytics into the universe of small molecules, helping scientists in their efforts to develop safer and more sustainable compounds.
“We are excited to collaborate with AsedaSciences, a company that aligns with our values and vision for the future of the pharmaceutical and chemical industries,” said Norman Azoulay, VP of Platforms & Data, Excelra. “By integrating the GOSTAR data within 3RnD, we provide access to our wealth of small molecules to the broader scientific community. This helps them tap into high-quality information and advance their small molecule programs while promoting safer design and environmental stewardship.”
This Co-marketing agreement between AsedaSciences and Excelra takes effect immediately. Both companies are committed to ensuring seamless integration and to jointly marketing the enhanced capabilities to their global customer bases.
